Roche Holding AG (ROG.S)
16 Nov 2018
Cancer drug developer Tesaro Inc is exploring a sale and is working with financial advisers after receiving takeover interest, Bloomberg reported on Friday, citing people familiar with the matter.
Nov 16 Cancer drug developer Tesaro Inc is exploring a sale and is working with financial advisers after receiving takeover interest, Bloomberg reported on Friday, citing people familiar with the matter.
U.S. drugmaker AbbVie Inc on Friday lowered its forecast for overseas sales of its top-selling medicine, Humira, due to larger-than-expected pricing cuts because of new competition in Europe.
Nov 2 U.S. drugmaker AbbVie Inc on Friday lowered its overseas sales forecast for its top-selling medicine, Humira, as it agreed to larger-than-expected price cuts due to new European competition.
Nov 2 AbbVie Inc beat Wall Street estimates for third-quarter profit and raised its earnings forecast for the year on Friday, driven by strong sales of blockbuster cancer medicine Imbruvica.
(This Oct 31 story corrects paragraph one to say targeted therapy, not immunotherapy)
Oct 31 AbbVie Inc and Roche Holding AG said on Wednesday their targeted therapy delayed the progression of a type of blood and bone marrow cancer when used in combination with the Swiss drugmaker's cancer drug in a late-stage trial.
ZURICH/BERLIN, Nov 1 The Swiss blue-chip SMI was seen opening down 0.4 percent down at 8,990 points on Thursday, according to premarket indications by bank Julius Baer.
* ROCHE ANNOUNCES EU APPROVAL OF VENCLYXTO PLUS MABTHERA FOR PEOPLE WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKAEMIA
* PHASE III DATA SHOWED THAT VENCLEXTA PLUS GAZYVA REDUCED THE RISK OF DISEASE WORSENING OR DEATH IN PEOPLE WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA WITH CO-MORBIDITIES